Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, nearly 5% of anti-TNF-treated patients with IBD developed psoriasiform skin lesions, with smoking identified as a main risk factor, and ustekinumab proved highly effective in severe cases.

This study found that recombinant human leukocyte interferon alfa-2a achieved a 64% overall antitumor response rate in patients with early and advanced cutaneous T cell lymphoma and was generally well-tolerated.

This paper reviews the use of interferons, particularly alfa interferon, in treating cutaneous T-cell lymphoma, noting its substantial efficacy both alone and in combination therapies with predictable, generally well-tolerated side effects.

This study investigated the impact of the JAK inhibitor ruxolitinib on APS-1 patients, reporting that treatment decreased excessive T-cell-derived interferon-γ, normalized inflammatory markers, and led to remission of several autoimmune symptoms without serious adverse effects.

This review discusses various presentations of drug-induced cutaneous eruptions, particularly those associated with interferon and ribavirin, and reports no new clinical findings.

In this study, a 10-year-old girl developed vitiligo and psoriasis during IFN-alfa treatment for chronic hepatitis B, with neither condition improving after stopping the therapy.

This study suggests that the neuropeptide CGRP may protect against, but not restore, IFNγ-induced collapse of hair follicle immune privilege in alopecia areata.

This case report documents a reversible instance of complete body hair loss (alopecia universalis) in a patient undergoing chronic hepatitis C treatment with pegylated interferon alpha-2b and ribavirin, with hair regrowth observed within three months after therapy completion.

In this study, a high daily dose of interferon alfa-2b administered initially six times a week for two weeks followed by thrice weekly for 12 weeks was most effective in sustaining normal ALT values in patients.

This article discusses alopecia areata occurring during Interferon Alpha-2b/Ribavirin therapy and reports no new clinical results.

This study reported that while lichen planus was not significantly linked to hepatitis C virus infection, pruritus, dry skin, and hair loss were more common in HCV patients post-interferon treatment.

This study reported two cases of alopecia universalis triggered by PEG-interferon and ribavirin therapy for chronic hepatitis C, with hair regrowth observed after therapy completion or withdrawal.

This study identifies substance P, TNFα, and IFNγ as novel regulators of prolactin and its receptor expression in human skin, suggesting intracutaneous prolactin is not controlled by dopamine.

This article reviews the therapeutic use of interferons and other cytokines in various viral, tumorous, and inflammatory diseases, discussing their biological effects and potential future applications without presenting new experimental results.

Targeting MIG and MCP-1 may help treat inflammation in alopecia areata.

This case report details an occurrence of Vogt-Koyanagi-Harada disease during pegylated interferon-α2b and ribavirin therapy for chronic hepatitis C.

This study found that intramuscular anti-IFN-γ significantly stabilized and promoted hair regrowth in alopecia areata patients with patchy, progressive hair loss, whereas those with total baldness showed more limited improvement.

A woman developed white patches on her skin and curly hair after hepatitis C treatment, likely due to the medication interferon alpha.

This study found that injecting interferon gamma into C3H/HeJ mice did not alter the frequency or onset of alopecia areata, suggesting the protein alone does not trigger the disease.

This study observed that interferon β secreted by dermal papilla cells may negatively regulate the growth of outer root sheath cells in hair follicles.

This study found that dermatological adverse events from interferon-alpha/ribavirin treatment for chronic hepatitis C are associated with factors like older age, pre-existing skin conditions, cirrhosis, and the use of pegylated interferon formulations.

This case report describes a 29-year-old woman with longstanding alopecia areata who experienced improvement in her scalp hair loss after 7 years of topical treatment with squaric acid dibutylester.

This study found that cutaneous ulcers caused by interferon are not associated with the medication's dosage.

This case report describes a rare instance of alopecia universalis occurring eight weeks after discontinuing pegylated interferon α and ribavirin therapy, highlighting the need for awareness among healthcare providers.

This report describes a case of alopecia universalis in a woman with hepatitis C linked to pegylated interferon alfa-2b and ribavirin therapy, with hair regrowth observed one year after discontinuation.

In this study, researchers reported that a newly developed interferon-γ release assay for cell-mediated immunity to SARS-CoV-2 nucleocapsid peptides demonstrated high sensitivity and specificity, making it a robust tool for routine diagnostic tests and potentially useful in predicting clinical outcomes after pathogen re-exposure.

This case report describes irreversible alopecia universalis following discontinuation of Peg-IFN/RBV treatment for chronic hepatitis C, highlighting potential autoimmune side effects of interferon-based therapies.

This case report identified dystrophic anagen effluvium as a previously unreported dermatological side effect of PEG-INF-α-2a/RBV combination therapy in a patient with chronic hepatitis C infection.

This article reports on a partial regrowth of scalp hair in a patient treated with extracorporeal photochemotherapy and interferon α 2a, but provides no new clinical outcomes.

In this study, pegylated interferon alpha therapy was independently associated with more severe hair loss, particularly acute telogen effluvium, in chronic hepatitis B patients with alopecia, compared to nucleos(t)ide analog therapy, emphasizing the importance of monitoring and counseling, especially for younger female patients.